Hayek, H., et al. Vaccine Adjuvants in the Immunocompromised Host: Science, Safety, and Efficacy.
Hayek, H., et al. Vaccine Adjuvants in the Immunocompromised Host: Science, Safety, and Efficacy. Transpl Infect Dis, 2025 May 19, e70053. PMID: 40387162 This comprehensi...
Read More
Hu, J., et al. Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity.
Hu, J., et al. Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity. Vaccine, 2025 May 31, 57:127241. PMID: 40354...
Read More
Shi, P., et al. Discovery of novel adjuvants: Identification of saponins from Hylomecon japonica (Thunb.) Prantl & Kündig and insights into their in vitro and in vivo activities.
Shi, P., et al. Discovery of novel adjuvants: Identification of saponins from Hylomecon japonica (Thunb.) Prantl & Kündig and insights into their in vitro and in vivo...
Read More
Lu, X., et al. Natural products targeting tumour angiogenesis.
Lu, X., et al. Natural products targeting tumour angiogenesis. Br J Pharmacol, 2025 May, 182(10):2094-2136. PMID: 37680009 This comprehensive review highlights the potent...
Read More
Alves, K., et al. Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
Alves, K., et al. Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: inte...
Read More
Natama, H.M., et al. Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Natama, H.M., et al. Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, pha...
Read More
Cao, H., et al. A QS21 + CpG-Adjuvanted Trivalent HSV-2 Vaccine and Trivalent HSV-2 mRNA Vaccine Induce a Strong Immune Response, Protect Against HSV-2 Infection, and Cross-Protect Against HSV-1 Infection in Mice.
Cao, H., et al. A QS21 + CpG-Adjuvanted Trivalent HSV-2 Vaccine and Trivalent HSV-2 mRNA Vaccine Induce a Strong Immune Response, Protect Against HSV-2 Infection, and Cr...
Read More
Adeagbo, B.A., et al. Lyophilization Strategy Enhances the Thermostability and Field-Based Stability of Conjugated and Comixed Subunit Liposomal Adjuvant-containing Tuberculosis Vaccine Formulation (ID93 + GLA-LSQ).
Adeagbo, B.A., et al. Lyophilization Strategy Enhances the Thermostability and Field-Based Stability of Conjugated and Comixed Subunit Liposomal Adjuvant-containing Tuber...
Read More